PMID- 34059950
OWN - NLM
STAT- MEDLINE
DCOM- 20211020
LR  - 20211020
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Linking)
VI  - 259
IP  - 11
DP  - 2021 Nov
TI  - The correlation between cytokine levels in the aqueous humor and the prognostic 
      value of anti-vascular endothelial growth factor therapy for treating macular 
      edema resulting from retinal vein occlusion.
PG  - 3243-3250
LID - 10.1007/s00417-021-05211-2 [doi]
AB  - PURPOSE: To determine the correlation between aqueous humor cytokine levels and 
      the prognostic value of anti-vascular endothelial growth factor (VEGF) therapy 
      for treating macular edema resulting from retinal vein occlusion (RVO-ME). 
      METHODS: This prospective study included 47 RVO-ME and 32 senile cataract cases. 
      Aqueous humor collection was performed in patients with RVO-ME before 
      intravitreal injection of ranibizumab and in patients before cataract surgery. 
      VEGF, monocyte chemotactic protein 1 (MCP-1), interleukin (IL)-8, IL-6, basic 
      fibroblast growth factor (b-FGF), and tumor necrosis factor-alpha (TNF-alpha) levels were 
      measured in the aqueous humor. Central retinal thickness (CRT) was measured 
      before ranibizumab treatment and during each follow-up visit. The recovery rate 
      following ranibizumab treatment was calculated as (CRT(BT)-CRT(AT1W))/CRT(BT), in 
      which CRT(BT) was the CRT measured before treatment and CRT(AT1W) was measured 
      1 week after treatment. The recurrence time of RVO-ME was recorded. RESULTS: 
      VEGF, MCP-1, IL-8, and IL-6 levels in the aqueous humor of patients with RVO-ME 
      were significantly higher compared with control and were positively correlated 
      with the CRT(BT). Ranibizumab significantly reduced CRT, and VEGF levels 
      positively correlated with the recovery rate. The mean recurrence time of RVO-ME 
      was 43.5 days. IL-6 levels negatively correlated with the recurrence time of ME. 
      CONCLUSION: VEGF, MCP-1, IL-8, and IL-6 levels were significantly increased in 
      patients with RVO-ME and were positively correlated with ME. Higher VEGF levels 
      were indicative of CRT recovery, and higher IL-6 levels were indicative of ME 
      recurrence after ranibizumab treatment.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Yong, Hongfang
AU  - Yong H
AD  - Department of Ophthalmology, The Second Hospital of Jilin University, Nanguan 
      District, Changchun, Jilin, 130041, China.
FAU - Qi, Hui
AU  - Qi H
AD  - Department of Ophthalmology, The Second Hospital of Jilin University, Nanguan 
      District, Changchun, Jilin, 130041, China.
FAU - Yan, Hongtao
AU  - Yan H
AD  - Department of Ophthalmology, The Second Hospital of Jilin University, Nanguan 
      District, Changchun, Jilin, 130041, China.
FAU - Wu, Qianqian
AU  - Wu Q
AD  - Department of Ophthalmology, The Second Hospital of Jilin University, Nanguan 
      District, Changchun, Jilin, 130041, China.
FAU - Zuo, Ling
AU  - Zuo L
AD  - Department of Ophthalmology, The Second Hospital of Jilin University, Nanguan 
      District, Changchun, Jilin, 130041, China. Zuoling@jlu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20210601
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Cytokines)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Aqueous Humor
MH  - Cytokines
MH  - Humans
MH  - Intravitreal Injections
MH  - *Macular Edema/diagnosis/drug therapy/etiology
MH  - Prognosis
MH  - Prospective Studies
MH  - Ranibizumab/therapeutic use
MH  - *Retinal Vein Occlusion/complications/diagnosis/drug therapy
MH  - Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A
OTO - NOTNLM
OT  - Cytokines
OT  - Macular edema
OT  - Prognosis
OT  - Retinal vein occlusion
EDAT- 2021/06/02 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/06/01 06:40
PHST- 2021/01/23 00:00 [received]
PHST- 2021/04/19 00:00 [accepted]
PHST- 2021/04/11 00:00 [revised]
PHST- 2021/06/02 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/06/01 06:40 [entrez]
AID - 10.1007/s00417-021-05211-2 [pii]
AID - 10.1007/s00417-021-05211-2 [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2021 Nov;259(11):3243-3250. doi: 
      10.1007/s00417-021-05211-2. Epub 2021 Jun 1.